1999
The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial
Berman R, Anand A, Cappiello A, Miller H, Hu X, Oren D, Charney D. The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biological Psychiatry 1999, 45: 1170-1177. PMID: 10331109, DOI: 10.1016/s0006-3223(98)00383-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultDepressive DisorderDouble-Blind MethodFemaleFluoxetineHumansMaleMiddle AgedPindololConceptsPlacebo groupClinical responseMore weeksDrug-free outpatientsEfficacy of pindololPartial remission rateUse of pindololPlacebo-controlled trialDouble-blind mannerMajor depressive episodeSingle-blind mannerPindolol groupPindolol treatmentPartial remissionRemission rateBlood pressureReuptake inhibitorsStudy endPatient populationDepressive episodeDepressed patientsMajor depressionRecurrent depressionSide effectsControl groupTransient Depressive Relapse Induced by Catecholamine Depletion: Potential Phenotypic Vulnerability Marker?
Berman RM, Narasimhan M, Miller HL, Anand A, Cappiello A, Oren DA, Heninger GR, Charney DS. Transient Depressive Relapse Induced by Catecholamine Depletion: Potential Phenotypic Vulnerability Marker? JAMA Psychiatry 1999, 56: 395-403. PMID: 10232292, DOI: 10.1001/archpsyc.56.5.395.Peer-Reviewed Original ResearchConceptsCatecholamine depletionMedication-free subjectsMajor depressionHamilton Depression Rating Scale scoresDepression Rating Scale scoresBaseline plasma cortisol levelsDepressive reactionsSignificant depressive symptomsRating Scale scoresHistory of depressionState-related alterationsPlasma cortisol levelsCatecholamine functionAlpha-methylparatyrosineRelapse criteriaBlood samplesDepressive symptomsCortisol levelsCrossover designScale scoreDepressed subjectsReliable markerTransient increaseVulnerability markerAnxiety symptoms
1997
Effects of Antiglucocorticoid Treatment on 5-HT1A Function in Depressed Patients and Healthy Subjects
Price L, Cappiello A, Malison R, McDougle C, Pelton G, Schöllnhammer G, Heninger G. Effects of Antiglucocorticoid Treatment on 5-HT1A Function in Depressed Patients and Healthy Subjects. Neuropsychopharmacology 1997, 17: 246-257. PMID: 9326749, DOI: 10.1016/s0893-133x(97)00049-3.Peer-Reviewed Original ResearchConceptsDepressed patientsReceptor functionHealthy control subjectsUnipolar depressed patientsAntiglucocorticoid treatmentAntidepressant actionGlucocorticoid modulationPreclinical findingsAdrenal axisControl subjectsAntidepressant activityClinical studiesTest doseHealthy subjectsReceptor sensitivityIpsapironeCortisol biosynthesisKetoconazoleDepressionPatientsBehavioral responsesSubjectsGlucocorticoidsAgonistsNeuroendocrine
1996
Seasonal Variation in Neuroendocrine and Mood Responses to IV L-Tryptophan in Depressed Patients and Healthy Subjects
Cappiello A, Malison R, McDougle C, Vegso S, Charney D, Heninger G, Price L. Seasonal Variation in Neuroendocrine and Mood Responses to IV L-Tryptophan in Depressed Patients and Healthy Subjects. Neuropsychopharmacology 1996, 15: 475-483. PMID: 8914120, DOI: 10.1016/s0893-133x(96)00057-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAffectDepressive DisorderFemaleHumansInjections, IntravenousMaleMiddle AgedProlactinSeasonsSingle-Blind MethodTryptophanConceptsHealthy subjectsTryptophan levelsDrug-free patientsVisual analog scaleL-tryptophanMale patientsAnalog scaleSerum prolactinDepressed patientsMajor depressionSerotonin functionNonpsychotic patientsMood disordersUnipolar patientsPatientsDSM-IIISuch abnormalitiesProlactinCosinor analysisMood responsesDepressionPrevious evidenceSubjectsInfusionNeuroendocrine